Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$10.8 million.

  • Vanda Pharmaceuticals' Net Cash Flow fell 32713.95% to -$10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.3 million, marking a year-over-year increase of 6346.92%. This contributed to the annual value of -$33.3 million for FY2024, which is 457543.62% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Net Cash Flow of -$10.8 million as of Q3 2025, which was down 32713.95% from -$30.9 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Net Cash Flow registered a high of $219.1 million during Q1 2023, and its lowest value of -$204.1 million during Q2 2023.
  • Moreover, its 5-year median value for Net Cash Flow was -$6.8 million (2021), whereas its average is $464052.6.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Net Cash Flow soared by 507872.73% in 2022 and then plummeted by 222423.14% in 2023.
  • Vanda Pharmaceuticals' Net Cash Flow (Quarter) stood at $1.6 million in 2021, then surged by 5078.73% to $85.4 million in 2022, then tumbled by 155.61% to -$47.5 million in 2023, then soared by 104.25% to $2.0 million in 2024, then plummeted by 633.45% to -$10.8 million in 2025.
  • Its Net Cash Flow stands at -$10.8 million for Q3 2025, versus -$30.9 million for Q2 2025 and $9.4 million for Q1 2025.